From June 24 to 26, the 23rd CPhI China 2025, the World Pharmaceutical Raw Materials Exhibition, was grandly held at the Shanghai New International Expo Centre. JiuZhou Pharma made a stunning appearance with teams from business, technology, and supply chain, showcasing its full-chain CDMO service capabilities and cutting-edge technological innovations. The company joined over 3,500 exhibitors and more than 100,000 professional visitors from around the world to explore new paths for innovation and development in the pharmaceutical industry.

Winning Two Industry Awards: Strengthening the Industry Benchmark

On the first day of the exhibition, at the "CPHI Celebration Awards & Networking Party" awards ceremony, JiuZhou Pharma won two prestigious awards: the "Global Preferred Partner Award" and the "ESG Responsibility Corporate Award." These accolades recognize the company’s exceptional one-stop service capabilities and successful practices in green and sustainable development. This achievement not only acknowledges the company’s years of dedication and innovation in the pharmaceutical field but also further consolidates its leading position in the global pharmaceutical market.

All-Cycle Service Matrix Captivates Attention: One-Stop Solutions Draw Focus

At booth W2A02, JiuZhou Pharma fully showcased its CDMO service system covering the entire lifecycle from preclinical research, process development, to commercial production. From in-depth exploration during the drug development phase to precise control in process transfer and optimization; from lean production in high-end custom manufacturing to efficient global supply chain management, JiuZhou Pharma attracted attention with its dual advantages of “technology-driven and efficient delivery.” Visitors from Europe, the U.S., Japan, South Korea, Southeast Asia, and other regions stopped by the booth, actively exploring cooperation opportunities.

The consulting and discussions at the booth were non-stop, with the exhibition team engaging deeply with customers on technical needs such as active pharmaceutical ingredient (API) development and complex formulation process optimization. The team provided professional and detailed answers to key requirements, such as project delivery cycles and customized solution designs. JiuZhou Pharma is currently advancing its product pipeline by using advanced technologies like chiral catalysis, continuous flow, fluorine chemistry, and synthetic biology, driving new drug development and continuously enhancing service efficiency. As the exhibition team stated, “We not only provide a full-service process from the lab to industrialization but also aim to transform technological innovations into our clients’ market competitiveness.” This full-chain empowerment model, from R&D to industrial implementation, has earned recognition from both domestic and international customers, providing strong momentum for business expansion.

Focusing on Industry Future Trends: Innovation-Driven Expansion of Service Boundaries

As an innovation-driven CDMO enterprise, JiuZhou Pharma has always been guided by global market trends, continuously expanding its service boundaries. While solidifying its core chemical small molecule business, the company is accelerating its expansion into frontier fields like peptide conjugates and small nucleic acid drugs. By attracting high-end international talent and building specialized R&D platforms, JiuZhou Pharma continues to drive the deep integration of innovative technologies with industrial demands.

At this exhibition, JiuZhou Pharma engaged with global customers on key products, market systems, and industry trends. Through sharing the latest technological developments, typical project cases, and profound industry insights, the company fully showcased its R&D competitive strength, flexible manufacturing capabilities, and global supply chain advantages. It joined hands with industry peers to explore new paths for the development of the pharmaceutical industry.

In recent years, JiuZhou Pharma has focused on pharmaceutical industry growth hotspots and global market trends, steadily advancing its global layout. Global production capacity construction is accelerating, and incremental business expansion is continuous. Cutting-edge technologies and high-quality services inject innovative vitality into collaborations, further bridging the gap with international markets.

Looking forward, JiuZhou Pharma will continue to adhere to an innovation-driven philosophy, accelerate its internationalization process, and work with industry peers to explore the path of high-quality development. The company is committed to contributing to the vigorous growth of the global pharmaceutical industry.

From June 24 to 26, the 23rd CPhI China 2025, the World Pharmaceutical Raw Materials Exhibition, was grandly held at the Shanghai New International Expo Centre. JiuZhou Pharma made a stunning appearance with teams from business, technology, and supply chain, showcasing its full-chain CDMO service capabilities and cutting-edge technological innovations. The company joined over 3,500 exhibitors and more than 100,000 professional visitors from around the world to explore new paths for innovation and development in the pharmaceutical industry.

Winning Two Industry Awards: Strengthening the Industry Benchmark

On the first day of the exhibition, at the "CPHI Celebration Awards & Networking Party" awards ceremony, JiuZhou Pharma won two prestigious awards: the "Global Preferred Partner Award" and the "ESG Responsibility Corporate Award." These accolades recognize the company’s exceptional one-stop service capabilities and successful practices in green and sustainable development. This achievement not only acknowledges the company’s years of dedication and innovation in the pharmaceutical field but also further consolidates its leading position in the global pharmaceutical market.

All-Cycle Service Matrix Captivates Attention: One-Stop Solutions Draw Focus

At booth W2A02, JiuZhou Pharma fully showcased its CDMO service system covering the entire lifecycle from preclinical research, process development, to commercial production. From in-depth exploration during the drug development phase to precise control in process transfer and optimization; from lean production in high-end custom manufacturing to efficient global supply chain management, JiuZhou Pharma attracted attention with its dual advantages of “technology-driven and efficient delivery.” Visitors from Europe, the U.S., Japan, South Korea, Southeast Asia, and other regions stopped by the booth, actively exploring cooperation opportunities.

The consulting and discussions at the booth were non-stop, with the exhibition team engaging deeply with customers on technical needs such as active pharmaceutical ingredient (API) development and complex formulation process optimization. The team provided professional and detailed answers to key requirements, such as project delivery cycles and customized solution designs. JiuZhou Pharma is currently advancing its product pipeline by using advanced technologies like chiral catalysis, continuous flow, fluorine chemistry, and synthetic biology, driving new drug development and continuously enhancing service efficiency. As the exhibition team stated, “We not only provide a full-service process from the lab to industrialization but also aim to transform technological innovations into our clients’ market competitiveness.” This full-chain empowerment model, from R&D to industrial implementation, has earned recognition from both domestic and international customers, providing strong momentum for business expansion.

Focusing on Industry Future Trends: Innovation-Driven Expansion of Service Boundaries

As an innovation-driven CDMO enterprise, JiuZhou Pharma has always been guided by global market trends, continuously expanding its service boundaries. While solidifying its core chemical small molecule business, the company is accelerating its expansion into frontier fields like peptide conjugates and small nucleic acid drugs. By attracting high-end international talent and building specialized R&D platforms, JiuZhou Pharma continues to drive the deep integration of innovative technologies with industrial demands.

At this exhibition, JiuZhou Pharma engaged with global customers on key products, market systems, and industry trends. Through sharing the latest technological developments, typical project cases, and profound industry insights, the company fully showcased its R&D competitive strength, flexible manufacturing capabilities, and global supply chain advantages. It joined hands with industry peers to explore new paths for the development of the pharmaceutical industry.

In recent years, JiuZhou Pharma has focused on pharmaceutical industry growth hotspots and global market trends, steadily advancing its global layout. Global production capacity construction is accelerating, and incremental business expansion is continuous. Cutting-edge technologies and high-quality services inject innovative vitality into collaborations, further bridging the gap with international markets.

Looking forward, JiuZhou Pharma will continue to adhere to an innovation-driven philosophy, accelerate its internationalization process, and work with industry peers to explore the path of high-quality development. The company is committed to contributing to the vigorous growth of the global pharmaceutical industry.

From June 24 to 26, the 23rd CPhI China 2025, the World Pharmaceutical Raw Materials Exhibition, was grandly held at the Shanghai New International Expo Centre. JiuZhou Pharma made a stunning appearance with teams from business, technology, and supply chain, showcasing its full-chain CDMO service capabilities and cutting-edge technological innovations. The company joined over 3,500 exhibitors and more than 100,000 professional visitors from around the world to explore new paths for innovation and development in the pharmaceutical industry.

Winning Two Industry Awards: Strengthening the Industry Benchmark

On the first day of the exhibition, at the "CPHI Celebration Awards & Networking Party" awards ceremony, JiuZhou Pharma won two prestigious awards: the "Global Preferred Partner Award" and the "ESG Responsibility Corporate Award." These accolades recognize the company’s exceptional one-stop service capabilities and successful practices in green and sustainable development. This achievement not only acknowledges the company’s years of dedication and innovation in the pharmaceutical field but also further consolidates its leading position in the global pharmaceutical market.

All-Cycle Service Matrix Captivates Attention: One-Stop Solutions Draw Focus

At booth W2A02, JiuZhou Pharma fully showcased its CDMO service system covering the entire lifecycle from preclinical research, process development, to commercial production. From in-depth exploration during the drug development phase to precise control in process transfer and optimization; from lean production in high-end custom manufacturing to efficient global supply chain management, JiuZhou Pharma attracted attention with its dual advantages of “technology-driven and efficient delivery.” Visitors from Europe, the U.S., Japan, South Korea, Southeast Asia, and other regions stopped by the booth, actively exploring cooperation opportunities.

The consulting and discussions at the booth were non-stop, with the exhibition team engaging deeply with customers on technical needs such as active pharmaceutical ingredient (API) development and complex formulation process optimization. The team provided professional and detailed answers to key requirements, such as project delivery cycles and customized solution designs. JiuZhou Pharma is currently advancing its product pipeline by using advanced technologies like chiral catalysis, continuous flow, fluorine chemistry, and synthetic biology, driving new drug development and continuously enhancing service efficiency. As the exhibition team stated, “We not only provide a full-service process from the lab to industrialization but also aim to transform technological innovations into our clients’ market competitiveness.” This full-chain empowerment model, from R&D to industrial implementation, has earned recognition from both domestic and international customers, providing strong momentum for business expansion.

Focusing on Industry Future Trends: Innovation-Driven Expansion of Service Boundaries

As an innovation-driven CDMO enterprise, JiuZhou Pharma has always been guided by global market trends, continuously expanding its service boundaries. While solidifying its core chemical small molecule business, the company is accelerating its expansion into frontier fields like peptide conjugates and small nucleic acid drugs. By attracting high-end international talent and building specialized R&D platforms, JiuZhou Pharma continues to drive the deep integration of innovative technologies with industrial demands.

At this exhibition, JiuZhou Pharma engaged with global customers on key products, market systems, and industry trends. Through sharing the latest technological developments, typical project cases, and profound industry insights, the company fully showcased its R&D competitive strength, flexible manufacturing capabilities, and global supply chain advantages. It joined hands with industry peers to explore new paths for the development of the pharmaceutical industry.

In recent years, JiuZhou Pharma has focused on pharmaceutical industry growth hotspots and global market trends, steadily advancing its global layout. Global production capacity construction is accelerating, and incremental business expansion is continuous. Cutting-edge technologies and high-quality services inject innovative vitality into collaborations, further bridging the gap with international markets.

Looking forward, JiuZhou Pharma will continue to adhere to an innovation-driven philosophy, accelerate its internationalization process, and work with industry peers to explore the path of high-quality development. The company is committed to contributing to the vigorous growth of the global pharmaceutical industry.